ErasmusMC
P. Hamberg, C.M.J.C. Seynaeve
A.E. van Leeuwen-Stok
Trialbureau ErasmusMC
No monitoring
Funding by KWF
Randomization: Arm A: trastuzumab given with docetaxel versus Arm B: sequential single agent therapy with trastuzumab followed by docetaxel
To assess whether the sequential arm (trastuzumab followed by the combination of trastuzumab and docetaxel at progression) has improved efficacy as compared with the combination of trastuzumab of docetaxel.
Primary endpoint:
Secondary endpoints:
